WHO | Penta

Jul, 2021

New findings from the ODYSSEY trial confirm superiority of dolutegravir-based ART in younger children

WHO welcomes new findings presented today at International Pediatric HIV Workshop on the superiority of dolutegravir (DTG)-based regimens in young children. Children living with HIV continue to be left behind by the global AIDS response. In 2020, only 54% of the 1.7 million children living with HIV received antiretroviral therapy in 2020 compared to 74% among adults living with HIV. Among the focus countries, only 40% of children living with HIV (or 74% of children receiving antiretroviral therapy) achieved viral suppression in 2020. The ODYSSEY trial, a multi-country randomised trial […]

Apr, 2021

Call for comments on the WHO Zika virus Research and Development Roadmap

Tags: ZIKA, WHO

The WHO is calling on the public to share their comments on the newly drafted Zika virus Research and Development (R&D) Roadmap, a key component of the WHO’s R&D Blueprint which is a global strategy and preparedness plan that allows the activation of R&D activities in advance of and during pandemics. Comments can be submitted by completing this form. The Zika virus R&D roadmap aims to accelerate the development and implementation of effective medical countermeasures for the Zika virus so as to reduce morbidity, mortality and transmission of the virus. Zika is […]

News

New findings from the ODYSSEY trial confirm superiority of dolutegravir-based ART in younger children

Call for comments on the WHO Zika virus Research and Development Roadmap

Global estimates of the relative pediatric consumption and cost of oral amoxicillin and amoxicillin plus clavulanic acid

Measuring research capacity development in healthcare workers: a systematic review

Early ART initiation during infancy preserves natural killer cells in young European adolescents living with HIV (CARMA cohort)

A conceptual approach to the rationale for SARS-CoV-2 vaccine allocation prioritisation